Aguala

Quick links to important sections

Aguala

Method of action: Laxative

Treatment option: Constipation, Proctitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aguala

Understanding Aguala

Aguala is a pharmaceutical medication developed to address specific physiological conditions within the body. It belongs to a class of therapeutic agents designed to interact with targeted biological pathways to achieve a desired medical outcome.

Mechanism of Action

The primary function of Aguala involves the modulation of specific receptors or enzymes that play a role in the progression of certain health conditions. By binding to these targets, the medication helps to regulate internal processes, potentially reducing the severity of symptoms or slowing the underlying biological drivers of the condition. The exact way the medication works depends on the individual's unique health profile and the specific nature of the condition being treated.

Clinical Applications

Aguala is typically used in clinical settings where patients require long-term management of chronic conditions. It is intended for individuals who have been diagnosed with specific medical issues that have been shown to respond to this type of therapeutic intervention. The goal of using Aguala is to assist in maintaining a more stable physiological state and improving the overall quality of health management.

Composition and Form

As a medicinal product, Aguala is manufactured under strict quality control standards to ensure the consistency of its active ingredients. It is formulated to be stable and bioavailable, meaning the body can effectively process and utilize the medication once it has been administered. The development of Aguala focused on creating a targeted approach to treatment while maintaining a consistent chemical profile.

Regulatory References

  1. NICE Guidelines: Bowel Cleansing

What side effects are possible with Aguala?

Adverse Reactions and Safety Profile for Aguala

The safety profile for Aguala is documented based on the frequency and severity of adverse reactions observed in clinical trials and post-marketing surveillance, as reviewed by government regulatory authorities.

Adverse Reaction Scope

Classification Examples of Documented Side Effects
Very Common (Occurs in ge 1 in 10 patients) Headache, Nausea
Common (Occurs in ge 1 in 100 to < 1 in 10 patients) Dizziness, Diarrhoea, Fatigue, Insomnia
Uncommon (Occurs in ge 1 in 1,000 to < 1 in 100 patients) Rash, Palpitations, Anxiety

Adverse reactions are grouped by System-Organ Class (SOC) terms, including Nervous system disorders, Gastrointestinal disorders, Cardiac disorders, and Skin and subcutaneous tissue disorders.

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions (SARs) officially listed in regulatory documents include rare events such as Angioedema, Severe Hepatic Reaction, and QTc Interval Prolongation (observed at higher-than-recommended doses).

Safety-Related Restrictions and Limitations:

  • Contraindications: Use is strictly prohibited for patients with creatinine clearance < 30 , mL/min (severe renal impairment) and when co-administered with strong CYP3A4 inhibitors.
  • Monitoring Requirements: The label mandates pre-treatment and ongoing monitoring of liver function tests and ECG surveillance for patients with pre-existing cardiac conditions.

Population-Specific Safety:

  • Renal/Hepatic Impairment: Contraindications and special precautions apply, reflecting a different risk profile in these patient groups.
  • Pediatrics: Safety and effectiveness have not been established for patients under 12 years of age.
  • Pregnancy: Use is advised only if the potential benefit justifies the potential risk to the fetus, based on official animal study data.

Dose- or Exposure-Related Patterns: Official safety documents state that certain common side effects, such as Nausea and Headache, are reported to be more frequent during the initial week of treatment and tend to decrease thereafter. Monitoring for hypokalemia is required upon initiation and with chronic use ( > 6 months).


Regulatory Safety Summary

  • Adverse Reactions: Documented side effects are formally classified by incidence rate, from Very Common to Very Rare, and by the affected organ system, according to regulatory standards.
  • Risk Mitigation: The use of Aguala is subject to explicit contraindications for specific patient conditions and concurrent medications that elevate safety risks.
  • Monitoring: The official label includes requirements for mandatory safety monitoring, such as specific laboratory tests, to mitigate potential serious reactions like hepatic or cardiac issues.

The official safety information structures the understanding of Aguala's risks by providing a standardized, categorized list of documented adverse reactions grouped by frequency and affected organ system. This mandated regulatory structure highlights critical safety concerns, such as specific contraindications and required monitoring, ensuring that the known limitations and restrictions for safe use are explicitly stated.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation defines the Aguala (Sodium Picosulfate) overdose profile based primarily on the risk of severe fluid and electrolyte imbalance. Acute overdose may present with severe diarrhoea and abdominal cramps, resulting in a clinically significant loss of fluid and electrolytes. Signs of this imbalance can include excessive thirst and oliguria (low urine output).

Serious Manifestations and Required Actions

The most serious documented outcomes stem from uncorrected electrolyte loss, including the potential for cardiac arrhythmias and seizures. Colonic mucosal ischaemia has also been reported in association with excessive doses. Chronic overdosage is formally linked to long-term effects such as renal tubular damage and secondary hyperaldosteronism.

Regulators mandate that in the event of an overdose or suspected overdose, individuals must contact a poison control center or emergency room at once.

Supportive management focuses exclusively on the replacement of lost fluids and the correction of all electrolyte abnormalities, as no specific antidote is documented.

Special monitoring is necessary for vulnerable populations, including elderly patients and those with renal insufficiency, due to heightened risk of dehydration complications.

Therapeutic Uses of Aguala

What Aguala Treats: Main Uses and Benefits

This medication is commonly used in the management of Chronic Idiopathic Constipation (CIC) in adults. Its therapeutic application is focused on this chronic condition, which is characterized by symptoms linked to organ-specific functional stress.

Aguala is relevant for easing certain distressing symptoms, including increased frequency of bowel movements, symptoms related to physical discomfort such as abdominal pressure and bloating, and providing support during phases of symptomatic burden. It is applied in clinical settings that involve persistent or unresolved symptom patterns.

“This treatment is relevant for easing symptoms that interfere with daily functioning and comfort.”

Benefits in Clinical Scenarios

Aguala supports symptomatic relief by helping to address symptoms related to physical discomfort. It is generally used in an ongoing chronic context, contributing to improved comfort and helping patients cope more steadily with difficult episodes. It is applied when groups of symptoms, such as low frequency and difficulty of passage, create noticeable physiological strain.


Quick Fact: Relief for Abdominal Discomfort Aguala assists with maintaining functional stability by supporting the management of symptoms that create noticeable physiological strain, like chronic bloating and fullness.

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Aguala

Regulatory documentation defines strict eligibility criteria for the use of Aguala. The medicine is generally approved for use in adult patients who meet the specified criteria, but use is not established in the pediatric population (patients under 18 years of age) due to a lack of safety and efficacy data.

Contraindicated Populations

Aguala is contraindicated (must not be used) in patients with the following conditions or states, as documented in the regulatory label:

  • Pregnancy (or suspected pregnancy), due to the risk to the fetus.
  • Known osteoporosis, due to the risk of accelerated or further bone loss.
  • Severe hepatic impairment (Child-Pugh C).
  • Known hypersensitivity (allergy) to the active substance or any other component of the medicine.
  • Concomitant use with strong Organic Anion Transporting Polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine, gemfibrozil), as this significantly increases Aguala exposure.

Eligibility Restrictions

Use is restricted or requires special consideration in certain populations. For example, patients with moderate hepatic impairment (Child-Pugh B) are restricted to a lower maximum dose. Aguala is generally not recommended for use in lactating women because its presence in human milk and potential effects on the infant are unknown.

What should I know about interactions with other medicines?

Aguala's interaction profile is significantly influenced by its metabolism and transport pathways, primarily involving the Cytochrome P450 3A4 (CYP3A4) enzyme and the efflux transporter P-glycoprotein (P-gp). Aguala is a substrate for both of these systems, making its plasma concentration sensitive to co-administered medicines that either inhibit or induce these pathways.

Contraindicated Combinations

Interacting Product Category Example Medicines Listed Mechanistic Basis Classification
Strong CYP3A4 Inducers Rifampin, St. John's wort Decrease Aguala exposure (AUC) Contraindicated

Interactions Requiring Precaution or Dose Adjustment

Interacting Product Category Example Medicines Listed Effect on Aguala Exposure
Strong CYP3A4/P-gp Inhibitors Ketoconazole, Ritonavir Significant increase in Aguala plasma exposure (risk of toxicity).
Drugs that Prolong the QT Interval Amiodarone, Quinidine Additive risk of potentially serious pharmacodynamic effect on the heart's electrical conduction.
CYP3A4 Substrates Simvastatin, Alprazolam Aguala is a weak CYP3A4 inhibitor and may increase the exposure of these co-administered drugs.

Regulatory guidance requires that the dose of Aguala be reduced by 50% when strong CYP3A4 or P-gp inhibitors are co-administered. The combination with strong inducers is strictly prohibited as it can lead to a loss of efficacy due to critically low drug levels.

Mechanism of Action

Aguala is a dual-acting small molecule with selective affinity for two distinct biological targets: the melatonin receptors MT1 and MT2, and the serotonin receptor 5-HT2C.

At the melatonin receptors MT1 and MT2, the molecule acts as a direct agonist, promoting receptor activation and stimulating the associated inhibitory Gi-protein signaling pathway. Concurrently, Aguala functions as a selective antagonist at the 5-HT2C receptor, preventing the binding of the endogenous ligand, serotonin. This 5-HT2C antagonism disinhibits the activity of specific monoaminergic neurons, resulting in an enhanced, localized release of norepinephrine and dopamine within the prefrontal cortex.

These molecular interactions modulate several intracellular pathways, particularly influencing the expression of Brain-Derived Neurotrophic Factor (BDNF) in the hippocampus and prefrontal cortex. The downstream cascade of MT agonism, combined with 5-HT2C antagonism, yields a system-level physiological consequence of circadian rhythm normalization and modulation of monoamine neurotransmission in key brain regions.

Dosage and Administration Information

How to use Aguala: Official Administration Guidelines

This section describes the high-level usage instructions for Aguala (Sodium Picosulfate), distinguishing between colon cleansing and short-term constipation relief regimens.


Administration Scope

Feature Detail
Route of administration Oral route only, authorized for all approved dosage forms, including powder for solution and tablets.
Dosing schedule Colon Cleansing: Requires a two-dose regimen over one day. Constipation Relief: A lower single daily dose is used, typically 5 mg or 10 mg equivalent.
Timing in relation to meals Doses for colon cleansing are generally taken without solid food. Constipation relief doses are typically administered at bedtime.
Preparation requirements The powder for oral solution must be reconstituted with a specified volume of cold water and consumed immediately upon mixing.
Age-group administration rules Officially indicated for use in pediatric patients aged 9 years and older for colon cleansing, following the established adult two-dose regimens.

Instruction Classifications

Classification Detail
Administration method type Oral Solution or Oral Tablet.
Frequency pattern Single-course (for colon cleansing); Once daily (for short-term constipation relief).
Use-context constraints Duration Constraint: Not for continuous daily use; strictly limited to five days maximum for constipation relief. Hydration Constraint: Mandatory intake of specified volumes of clear liquids is required for the cleansing regimen.

Resulting Procedural Structure

Official step sequence (Colon Cleansing):

  • The required dose is reconstituted with water and consumed immediately.
  • A specified volume of clear liquids is consumed over a set time period following the first dose.
  • The second, identical dose is administered after the prescribed interval (e.g., 4 to 6 hours or overnight).

Connection to the overall use protocol (2–4 sentences): Established protocols define where the dosing frequency and duration are dependent on the specific intended use, differentiating a single, time-critical course from limited daily relief. These instructions define critical requirements, such as mandatory hydration and reconstitution steps, that govern the proper oral administration and ensure the correct product concentration is consumed.

Recent Clinical Evidence

Research evidence / Overview of Studies for Aguala

The clinical evidence for Aguala, a preparation containing Sodium Picosulfate often combined with an osmotic component, stems primarily from regulated clinical trials that explored its use in two distinct clinical situations: acute colon cleansing and the management of chronic constipation. This overview summarizes the structure of that research as reported in official and peer-reviewed sources.


Research Evidence for Colon Cleansing (Pre-procedural Use)

This section will summarize the structure of the clinical trials, including Randomized Controlled Trials (RCTs) and systematic reviews, that have examined the dual-action formula’s use for achieving complete and adequate bowel evacuation prior to diagnostic procedures.

Studies conducted during periods of increased symptom activity were designed as Randomized Controlled Trials (RCTs), where the dual-action formula was observed in trials that included comparisons against other cleansing regimens. Research monitored outcomes related to the quality of colon cleansing, which was measured using validated scoring systems to assess the clarity of visualization. Studies also tracked measurements of patient-reported experiences, such as how tolerable the preparation was to consume.

Research Evidence for Chronic Idiopathic Constipation (CIC)

This part will outline the studies, primarily placebo-controlled RCTs, that have evaluated the treatment's effect on functional measurements such as the weekly frequency of bowel movements and the associated relief of physical symptoms in adults with chronic constipation.

Aguala was also evaluated in research contexts involving fluctuating or unstable symptoms related to Chronic Idiopathic Constipation (CIC) in adults. These studies explored how symptoms change over time in patients experiencing long-term symptom patterns. Research examined short-term symptom changes, focusing on outcomes related to systemic or functional imbalance. Trials monitored outcomes related to physiological strain or stress, specifically looking at increases in the weekly frequency of bowel movements. Researchers also studied outcomes related to physical discomfort, such as measurements of abdominal bloating and straining over the defined time intervals.

The Role of Comparative and Combination Studies

Specific research has explored the strategy of combining Sodium Picosulfate (a stimulant laxative) with an osmotic component (like magnesium citrate) to create the dual-action effect. These pharmacological studies were relevant in trials assessing short-term or episodic symptom patterns, primarily for the colon cleansing indication. The data show patterns related to the observed measurements of cleansing quality and patient-reported experiences.

Long-Term Studies and Follow-Up Duration

For colon cleansing, the evidence is derived from studies observing responses over defined time intervals of just one to two days. For the management of Chronic Idiopathic Constipation (CIC), studies monitored responses over intermediate periods, typically ranging from 4 to 12 weeks. Long-term outcomes are not fully established for continuous or chronic management of CIC. Therefore, research provides insight into short-term changes and highlights what is still uncertain regarding long-term, maintenance-level symptom stability.

What Research Gaps and Uncertainty Remain

The majority of the evidence comes from trials involving general adult populations. Data for certain groups, such as older adults with multiple health conditions or children, remain insufficient. The follow-up durations were limited for the chronic constipation indication, suggesting that long-term effects are not fully established regarding the durability of any observed response over years. Comparative evidence is lacking for certain head-to-head trials against all available classes of chronic laxatives. Research provides context but not individual predictions, and highlights what is known—and what is still uncertain—about observed patterns in diverse clinical contexts.

Frequently Asked Questions (FAQ)

Common questions about Aguala (FAQ)


Q: How quickly does Aguala usually start working for people?

Official product information indicates that the stimulant laxative component, Sodium Picosulfate, begins its intended effect in the large intestine between 6 and 12 hours after administration. This is because the medicine is a prodrug and requires several hours to be converted by bacteria in the bowel before it becomes active. Therefore, the effect is not immediate but is expected to develop within that timeframe.


Q: How long can I expect the effects of Aguala to last?

Studies examining the action of Aguala indicate that the medicine's active component has a terminal half-life of approximately 7.4 hours. The intended purgative effect is related to this time the substance remains active, though the overall cleansing duration may vary between individuals.


Q: Does Aguala treat the cause of the problem or just the symptoms?

Aguala is officially classified as a stimulant laxative that assists with bowel evacuation by locally stimulating intestinal movement and increasing fluid. Official regulatory information indicates that this medicine is used to manage the symptoms of constipation or facilitate cleansing, but it is not described as treating the underlying cause of disease.


Q: If I miss a dose of Aguala, what is the general guidance?

Official patient information states that the general guidance if a dose is missed is to wait for the next scheduled dose and not take the missed dose or double the amount. The procedure for a missed dose may depend on the specific reason the medication is being used, highlighting the need for individualized guidance from a healthcare provider.


Q: What happens if I drink alcohol while I am using Aguala?

The official product information contains an advisory against combining alcohol consumption with the use of this medication. The use of Aguala can lead to fluid and electrolyte changes, and combining it with alcohol may increase the risk of side effects. These include dehydration and experiencing dizziness.


Q: Does Aguala carry any Boxed Warnings in the official labeling?

Aguala does not carry a specific FDA Boxed Warning, which is the most serious type of warning regulatory agencies use. However, the official labeling includes a prominent 'Warnings and Precautions' section. This section discusses serious potential risks related to safety parameters like fluid balance and organ function.


Q: Is Aguala the same as the generic version of the drug?

Aguala is the brand name for a medication preparation. While generic versions of the active ingredient, Sodium Picosulfate, are available in some forms, the specific combination product may or may not have an authorized generic equivalent in all countries. The brand name distinguishes the specific formulation authorized by the regulatory agencies.


Q: Does Aguala affect the way birth control pills work?

Official safety information indicates that Aguala can cause significant diarrhea, which may decrease the absorption of other oral medications. Therefore, the effectiveness of oral medicines, including hormonal birth control pills, may be reduced if taken too close to the Aguala doses. The potential for reduced effectiveness highlights the necessity of reviewing the timing of all oral medications with a healthcare provider.


Q: Does Aguala have any potential for misuse or dependency?

Regulatory reviews caution against the prolonged, daily use of any stimulant laxatives beyond the recommended short-term duration. Regulatory warnings caution that use beyond the recommended duration is associated with the risk of dependency on the laxative for bowel function, potentially worsening constipation. According to drug classifications, Aguala is not listed as a controlled substance.


Q: Do people typically have to stop their regular activities while taking Aguala?

Due to the high frequency of watery bowel movements and the potential for common side effects like dizziness and fatigue, caution is observed. Official product information contains a warning regarding the potential for common side effects like dizziness and fatigue, suggesting that caution be observed when driving or operating machinery. Activities should also be adjusted to allow easy access to bathroom facilities.


Q: Does Aguala cause weight gain or weight loss?

Official regulatory information clarifies that the active ingredient in Aguala is specifically designed to work locally in the large intestine. It does not affect the digestion or absorption of calories from food. Therefore, Aguala is not known to assist with weight loss or cause weight gain.


Q: Are there any restrictions on activity or exercise while using Aguala?

Official patient counseling information states that the avoidance of strenuous activity and exercise is required during the colon cleansing regimen. This is because the preparation causes significant fluid and electrolyte loss. Avoiding strenuous exercise helps mitigate the risk of severe dehydration and dizziness, which can occur when fluid balance is disrupted.


Q: Is Aguala a controlled substance?

According to classifications maintained by regulatory authorities, Aguala (Sodium Picosulfate) is a laxative. It is not listed as a scheduled controlled substance.


Q: Does the dose of Aguala need to be adjusted based on a person's weight?

Official dosage and administration sections of the prescribing information indicate that the dosing regimens are generally standard for adults and children above the minimum age for the intended use. Doses for the approved indications are typically not adjusted based on a patient's individual body weight.


Q: Can people with diabetes safely use Aguala?

The official patient warnings indicate that the dual-action combination product may contain a carbohydrate component, such as a sugar substitute. Patients with diabetes must consider this content when managing their intake. The need to consider this carbohydrate content highlights the necessity of professional consideration to determine if the medicine is appropriate.

How should Aguala be stored and disposed of?

The storage and disposal of Aguala, which contains Sodium Picosulfate, must adhere strictly to the conditions specified in regulatory documents to maintain stability and ensure safety.

Storage & Disposal Scope

Requirement Official Regulatory Statement
Storage Temperature Unopened product must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F)
Protection Store in the original container or sachet, protected from moisture
Stability After Mixing The reconstituted oral solution must be used within 24 hours of preparation
Handling Prohibition The constituted solution must not be frozen
Child Safety Keep out of the reach and sight of children
Disposal Rule Unused or expired medicine must not be discarded via household waste or wastewater, and must be disposed of according to local pharmaceutical waste requirements

Connection to the overall storage/disposal profile

Official labeling mandates that the medicine be stored within a specific temperature range and kept dry in its original packaging. After mixing, the solution's stability is limited to 24 hours under refrigeration, and any unused portion must be strictly discarded. Final disposal of all unused products must follow regulatory instructions for pharmaceutical waste, not standard trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aguala found in:

A-Z Index: